Catalytic Enantioselective Addition of Organometallic Reagents to <i>N</i>-Formylimines Using Monodentate Phosphoramidite Ligands
作者:Maria Gabriella Pizzuti、Adriaan J. Minnaard、Ben L. Feringa
DOI:10.1021/jo702140f
日期:2008.2.1
The asymmetricsynthesis of protected amines via the copper/phosphoramidite-catalyzed addition of organozinc and organoaluminum reagents to N-acylimines, generated in situ from aromatic and aliphatic α-amidosulfones, is reported. High yields of optically active N-formyl-protected amines and enantioselectivities up to 99% were obtained. Under the reaction conditions, partial oxidation of the phosphoramidite
The Asymmetric Dialkylzinc Addition to Imines Catalyzed by [2.2]Paracyclophane-Based <i>N</i>,<i>O</i>-Ligands
作者:Stefan Dahmen、Stefan Bräse
DOI:10.1021/ja025831e
日期:2002.5.1
enantioselective dialkylzincaddition to imines in the presence of catalytic amounts of N,O-ligands is reported. N-formyl-alpha-(p-tolysulfonyl)benzylamines are the readily available starting materials easily obtained in a one-pot synthesis from benzaldehydes, formamide, and p-tolylsulfinic acid. Upon deprotonation, the sulfinate is eliminated to give the acyl imine. The acyl imines further react with
据报道,在催化量的 N,O-配体存在下,首次对亚胺具有高度对映选择性的二烷基锌加成。N-甲酰基-α-(对甲苯磺酰基)苄胺是容易获得的起始原料,可通过苯甲醛、甲酰胺和对甲苯基亚磺酸一锅法合成。去质子化后,亚磺酸盐被消除,得到酰基亚胺。在催化量的基于 [2.2] 对环芳烷的 N,O-配体 L 的存在下,酰基亚胺进一步与烷基锌试剂反应,产生具有优异产率和对映选择性的烷基化 N-(1-苯丙基)甲酰胺。
Development of Chiral Catalysts by Asymmetric Activation for Highly Enantioselective Diethylzinc Addition to Imines
derived from chiral 1,2-diphenyl-ethanene-1,2-diamine, BINOL derivatives, and diethylzinc are evaluated in the asymmetric addition of diethylzinc to N-acylimines. In the presence of 10 mol% L3ZnAl, high enantioselectivities and yields were provided for a wide range of aromatic imines in 1,2-dichloroethane at -25 °C.
The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.